Mocravimod
Priothera is developing mocravimod, a S1P receptor modulator, with the aim of enhancing the curative potential of allo-HCT.
Promising early clinical results have revealed that mocravimod has the potential to decouple Graft-versus-host disease (GvHD) from Graft-versus-Leukemia (GvL), by preventing GvHD while preserving GvL.
Mocravimod binds to different S1P receptors with different affinities
Promising early clinical results have revealed that mocravimod has four mode of actions
01
Retention of functional T cells in lymphoid organs, decouples Graft-versus-Host Disease (GVHD) from Graft-versus-Leukemia (GVL) resulting in prevention of GvHD while preserving GvL.
binds to different S1P receptors with different affinities
02
Reduction of peripheral inflammatory cytokines
03
CAR T cell activation.
04
Induction of death of blood cancer cells.
Priothera has acquired Mocravimod (KRP203) from Japanese Pharmaceutical company KYORIN Pharmaceutical.